Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism by Yilan Yang, Jiatao Liao, Zhe Pan, Jin Meng, Li Zhang, Wei Shi, Xiaofang Wang, Xiaomeng Zhang, Zhirui Zhou, Jurui Luo, Xingxing Chen, Zhaozhi Yang, Xin Mei, Jinli Ma, Zhen Zhang, Yi‐Zhou Jiang, Zhi‐Min Shao, Fei Xavier Chen, Xiaoli Yu, Xiaomao Guo

Subjects: Get full text

Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study by Seda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, Deniz Can Guven, Ozge Gumusay, Basak Oyan Uluc, Ertugrul Bayram, Burcu Gulbagci, Alper Yasar, Sena Ece Davarci, Eda Eylemer Mocan, Omer Acar, Deniz Isik, Esra Aydin, Yusuf Karakas, Melike Ozcelik, Murat Keser, Sadi Kerem Okutur, Onder Eren, Serkan Menekse, Dincer Aydin, Funda Yilmaz, Ozlem Dogan, Gulhan Ozkanli, Hakan Yucel, Veli Sunar, Musa Baris Aykan, Ozlem Ozdemir, Berna Bozkurt Duman, Merve Keskinkilic, Teoman Sakalar, Ali Inal, Muge Karaoglanoglu, Asude Aksoy, Muhammed Muhiddin Er, Nazim Serdar Turhal, Nurhan Onal Kalkan, Mehmet Ali Nahit Sendur

Subjects: “…CDK 4/6 inhibitors…”
Get full text

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]) by A. DeMichele, A. C. Dueck, D. Hlauschek, M. Martin, H. Burstein, G. Pfeiler, N. Zdenkowski, A. Wolff, M. Bellet-Ezquerra, E. Winer, M. Balic, K. Miller, M. Colleoni, D. Lake, G. Rubovsky, D. Cameron, J. Balko, C. F. Singer, Z. Nowecki, H. Iwata, N. Wolmark, K. A. Parraga, H. Rugo, G. G. Steger, T. Traina, G. Werutsky, D. Czajkowska, O. Metzger, S. El-Abed, K. P. Theall, R. D. Lu, P. O’Brien, C. Fesl, E. Mayer, M. Gnant

Subjects: Get full text

Thiazolo-pyridopyrimidines: An in silico evaluation as a lead for CDK4/6 inhibition, synthesis and cytotoxicity screening against breast cancer cell lines by Chaithra R Shetty, C. S. Shastry, Parasuraman P, Srinivas Hebbar

Subjects: Get full text

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them by L. Foffano, L. Cucciniello, E. Nicolò, I. Migliaccio, C. Noto, C. Reduzzi, L. Malorni, M. Cristofanilli, L. Gerratana, F. Puglisi

Subjects: Get full text

Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis by Roberto Buonaiuto, Aldo Caltavituro, Margherita Tafuro, Alessandra Longobardi, Giuliana Pavone, Pierluigi De Santis, Roberta Caputo, Carmine De Angelis, Lucia Del Mastro, Fabio Puglisi, Mario Giuliano, Grazia Arpino, Martina Pagliuca, Michelino De Laurentiis

Subjects: Get full text

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer by Paola Zagami, Angela Esposito, Beatrice Taurelli Salimbeni, Pier Paolo Maria Berton Giachetti, Roberta Scafetta, Matteo Lambertini, Massimo Di Maio, Giuseppe Curigliano, Carmen Criscitiello, Saverio Cinieri

Subjects: Get full text

Safety of Abemaciclib in Indian Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced and/or Metastatic Breast Cancer: A Multi... by Dinesh Chandra Doval, Tanveer Maksud, Rajnish Nagarkar, Satheesh Chiradoni Thunagappa, Rakesh Taran, Saurabh Prasad, Anoop T. Manoharan, Minish Jain, Dhruv Mehta, Prabrajya Narayan Mohapatra, Sachin Gupta, Kritarth Naman Singh, Aarohan Pruthi, Rohit Arora

Subjects: Get full text

RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer by Charlotte K. Kindt, Sidse Ehmsen, Sidse Ehmsen, Sidse Ehmsen, Sofie Traynor, Benedetta Policastro, Nikoline Nissen, Mie K. Jakobsen, Monique F. Hundebøl, Lene E. Johansen, Martin Bak, Elsa Arbajian, Johan Staaf, Henrik J. Ditzel, Henrik J. Ditzel, Henrik J. Ditzel, Carla L. Alves

Subjects: Get full text

Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments by Belluzzi L, Martinelli G, Medici B, Farina A, Martinelli E, Canino F, Caggia F, Molinaro A, Barbolini M, Tamburrano F, Moscetti L, Piacentini F, Dominici M, Omarini C

Subjects: Get full text

Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors by Baković Matea, Bago Martina, Benić Lucija, Krajinović Magdalena, Silovski Tajana, Plavetić Natalija Dedić, Turković Lu, Sertić Miranda, Hadžiabdić Maja Ortner

Subjects: Get full text

Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study by Akif Doğan, Nurullah İlhan, Goncagül Akdağ, Sedat Yıldırım, Mustafa Seyyar, Zeynep Yüksel Yaşar, Hande Nur Erölmez, Heves Sürmeli, Buğra Öztosun, Özlem Nuray Sever, Hatice Odabaş, Mahmut Emre Yıldırım, Devrim Çabuk, Nedim Turan, Mahmut Gümüş

Subjects: Get full text

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer by Carlos M Roggero, Anwesha B Ghosh, Anvita Devineni, Shihong Ma, Eliot Blatt, Ganesh V. Raj, Yi Yin

Subjects: Get full text

Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors by Neha Pathak, Abhenil Mittal, Sudhir Kumar, Chitrakshi Nagpal, Eitan Amir, Partha Haldar, Bharath B. Gangadharaiah, Akash Kumar, Ashutosh Mishra, Atul Batra

Subjects: Get full text